These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 23206898)

  • 21. Immune response to 2009 pandemic H1N1 influenza virus A monovalent vaccine in children with cancer.
    Yen TY; Jou ST; Yang YL; Chang HH; Lu MY; Lin DT; Lin KH; Huang LM; Chang LY
    Pediatr Blood Cancer; 2011 Dec; 57(7):1154-8. PubMed ID: 21425448
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Are plasma mineral levels related to antibody response to influenza vaccination in older adults?
    Kaynar AM; Nowalk MP; Lin CJ; Moehling KK; Susick M; Bakalov V; Pitt BR; Bain DJ; Ross TM; Saul SG; Raymund M; Zimmerman RK
    Hum Vaccin Immunother; 2016 Apr; 12(4):1003-8. PubMed ID: 26751915
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mycophenolate and lower graft function reduce the seroresponse of kidney transplant recipients to pandemic H1N1 vaccination.
    Mulley WR; Visvanathan K; Hurt AC; Brown FG; Polkinghorne KR; Mastorakos T; Lewicki MC; Stuart RL; Tan SJ; Chean R; Kerr PG; Kanellis J
    Kidney Int; 2012 Jul; 82(2):212-9. PubMed ID: 22495292
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Seroresponse to Inactivated and Recombinant Influenza Vaccines Among Maintenance Hemodialysis Patients.
    Manley HJ; Lacson EK; Aweh G; Chen Li N; Weiner DE; Miskulin DC; Hsu CM; Kapoian T; Hayney MS; Meyer KB; Johnson DS
    Am J Kidney Dis; 2022 Sep; 80(3):309-318. PubMed ID: 35288216
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The priming effect of previous natural pandemic H1N1 infection on the immunogenicity to subsequent 2010-2011 influenza vaccination in children: a prospective cohort study.
    Kang EK; Eun BW; Kim NH; Lim JS; Lee JA; Kim DH
    BMC Infect Dis; 2016 Aug; 16(1):438. PubMed ID: 27549626
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunogenicity, boostability, and sustainability of the immune response after vaccination against Influenza A virus (H1N1) 2009 in a healthy population.
    Huijskens E; Rossen J; Mulder P; van Beek R; van Vugt H; Verbakel J; Rimmelzwaan G; Koopmans M; Peeters M
    Clin Vaccine Immunol; 2011 Sep; 18(9):1401-5. PubMed ID: 21795459
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterization and long-term persistence of immune response following two doses of an AS03A-adjuvanted H1N1 influenza vaccine in healthy Japanese adults.
    Ikematsu H; Nagai H; Kawashima M; Kawakami Y; Tenjinbaru K; Li P; Walravens K; Gillard P; Roman F
    Hum Vaccin Immunother; 2012 Feb; 8(2):260-6. PubMed ID: 22426369
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The humoral immune response of hematopoietic stem cell transplantation recipients to AS03-adjuvanted A/California/7/2009 (H1N1)v-like virus vaccine during the 2009 pandemic.
    Engelhard D; Zakay-Rones Z; Shapira MY; Resnick I; Averbuch D; Grisariu S; Dray L; Djian E; Strauss-Liviatan N; Grotto I; Wolf DG; Or R
    Vaccine; 2011 Feb; 29(9):1777-82. PubMed ID: 21216315
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Influenza Vaccine-Induced Antibody Responses Are Not Impaired by Frailty in the Community-Dwelling Elderly With Natural Influenza Exposure.
    Narang V; Lu Y; Tan C; Camous XFN; Nyunt SZ; Carre C; Mok EWH; Wong G; Maurer-Stroh S; Abel B; Burdin N; Poidinger M; Tambyah PA; Bosco N; Visan L; Ng TP; Larbi A
    Front Immunol; 2018; 9():2465. PubMed ID: 30405641
    [No Abstract]   [Full Text] [Related]  

  • 30. Safety and immunogenicity of an MF59-adjuvanted A/H1N1 pandemic influenza vaccine in children from three to seventeen years of age.
    Knuf M; Leroux-Roels G; Rümke HC; Abarca K; Rivera L; Lattanzi M; Pedotti P; Arora A; Kieninger-Baum D; Della Cioppa G
    Vaccine; 2015 Jan; 33(1):174-81. PubMed ID: 25444803
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunogenicity of AS03-adjuvanted and non-adjuvanted trivalent inactivated influenza vaccines in elderly adults: A Phase 3, randomized trial and post-hoc correlate of protection analysis.
    Ruiz-Palacios GM; Leroux-Roels G; Beran J; Devaster JM; Esen M; Launay O; McElhaney JE; van Essen GA; Benoit A; Claeys C; Dewé W; Durand C; Duval X; Falsey AR; Feldman G; Galtier F; Gervais P; Hwang SJ; McNeil S; Richardus JH; Trofa A; Oostvogels L;
    Hum Vaccin Immunother; 2016 Dec; 12(12):3043-3055. PubMed ID: 27690762
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Randomized Trial of Two 2-Dose Influenza Vaccination Strategies for Patients Following Autologous Hematopoietic Stem Cell Transplantation.
    Teh BW; Leung VKY; Mordant FL; Sullivan SG; Joyce T; Harrison SJ; Khvorov A; Barr IG; Subbarao K; Slavin MA; Worth LJ
    Clin Infect Dis; 2021 Dec; 73(11):e4269-e4277. PubMed ID: 33175132
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Profiles of influenza A/H1N1 vaccine response using hemagglutination-inhibition titers.
    Jacobson RM; Grill DE; Oberg AL; Tosh PK; Ovsyannikova IG; Poland GA
    Hum Vaccin Immunother; 2015; 11(4):961-9. PubMed ID: 25835513
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunogenicity of influenza A(H1N1)pdm09 vaccine and the associated factors on lowered immune response in patients with hepatitis C.
    Ohfuji S; Fukushima W; Tamori A; Maeda K; Maeda A; Hirota Y
    Influenza Other Respir Viruses; 2013 May; 7(3):456-65. PubMed ID: 22897938
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of pre-existing immunity on the induction of functional cross-reactive anti-hemagglutinin stalk antibodies following vaccination with an AS03 adjuvanted pandemic H1N1 vaccine.
    Tete SM; Jul-Larsen Å; Rostami S; Lunde THF; Søland H; Krammer F; Cox RJ
    Vaccine; 2018 Apr; 36(16):2213-2219. PubMed ID: 29548607
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Response to 2009 pandemic influenza A (H1N1) vaccine in HIV-infected patients and the influence of prior seasonal influenza vaccination.
    Soonawala D; Rimmelzwaan GF; Gelinck LB; Visser LG; Kroon FP
    PLoS One; 2011 Jan; 6(1):e16496. PubMed ID: 21304982
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antibody levels in a cohort of pregnant women after the 2009 influenza A(H1N1) pandemic: Waning and association with self-reported severity and duration of illness.
    Tunheim G; Laake I; Robertson AH; Waalen K; Hungnes O; Naess LM; Cox RJ; Mjaaland S; Trogstad L
    Influenza Other Respir Viruses; 2019 Mar; 13(2):191-200. PubMed ID: 30536590
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Unadjuvanted pandemic H1N1 influenza vaccine in HIV-1-infected adults.
    Hatakeyama S; Iwatsuki-Horimoto K; Okamoto K; Nukui Y; Yata N; Fujita A; Inaba S; Yotsuyanagi H; Kawaoka Y
    Vaccine; 2011 Nov; 29(49):9224-8. PubMed ID: 21978767
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine: results from a double-blinded, randomized Phase I clinical trial in healthy Asian volunteers.
    Low JG; Lee LS; Ooi EE; Ethirajulu K; Yeo P; Matter A; Connolly JE; Skibinski DA; Saudan P; Bachmann M; Hanson BJ; Lu Q; Maurer-Stroh S; Lim S; Novotny-Diermayr V
    Vaccine; 2014 Sep; 32(39):5041-8. PubMed ID: 25045806
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Absence of cross-reactive antibodies to influenza A (H1N1) 2009 before and after vaccination with 2009 Southern Hemisphere seasonal trivalent influenza vaccine in children aged 6 months-9 years: a prospective study.
    McVernon J; Laurie K; Barr I; Kelso A; Skeljo M; Nolan T
    Influenza Other Respir Viruses; 2011 Jan; 5(1):7-11. PubMed ID: 21138535
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.